Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Oct 29;4(11):2514-57.
doi: 10.3390/v4112514.

Advanced vaccine candidates for Lassa fever

Igor S Lukashevich  1
Affiliations
Review

Advanced vaccine candidates for Lassa fever

Igor S Lukashevich. Viruses. .

Abstract

Lassa virus (LASV) is the most prominent human pathogen of the Arenaviridae. The virus is transmitted to humans by a rodent reservoir, Mastomys natalensis, and is capable of causing lethal Lassa Fever (LF). LASV has the highest human impact of any of the viral hemorrhagic fevers (with the exception of Dengue Fever) with an estimated several hundred thousand infections annually, resulting in thousands of deaths in Western Africa. The sizeable disease burden, numerous imported cases of LF in non-endemic countries, and the possibility that LASV can be used as an agent of biological warfare make a strong case for vaccine development. Presently there is no licensed vaccine against LF or approved treatment. Recently, several promising vaccine candidates have been developed which can potentially target different groups at risk. The purpose of this manuscript is to review the LASV pathogenesis and immune mechanisms involved in protection. The current status of pre-clinical development of the advanced vaccine candidates that have been tested in non-human primates will be discussed. Major scientific, manufacturing, and regulatory challenges will also be considered.

PubMed Disclaimer

Figures

Figure 1 (a)
Figure 1 (a)
Risk map of Lassa Fever in West Africa. Positive localities indicated by stars. The posterior probability color scale, from 0.0 (no risk) to 1.0 (highest risk) is shown as an inset. From E. Fichet-Calvet, D.J. Rogers [3] with permission.
Figure 1 (b)
Figure 1 (b)
Phylogenetic relationships among the Old World arenaviruses (grey sector) based on analysis of the NP gene. From A. Ishii et al with permission [10]. See text for more details.
Figure 2
Figure 2
Advanced alphavirus-based vector technology. The 1st generation was based on Venezuelan equine encephalitis virus (VEEV) and required BSL-3 containment. Replication-competent virus (RCV) can be generated during a recombination event. In the 2nd generation, vectors use human vaccine VEEV TC-83 vaccine backbone and transcription of helper genes is controlled by non-related CMV (cytomegalovirus) promoter. Helper proteins (capsid and glycoproteins, E1&E2) can be made from two mono-cistronic CMV-plasmids or from one CMV-bicistronic plasmid (see text). Recombination events are minimized and BSL2 containment is required for production ([126]; Pushko & Lukashevich, unpublished.
Figure 3
Figure 3
The predicted structure of GP2 glycoprotein of ML29. The non-conservative K272E substitution (marked by star) located between two fusion domains at N-terminus introduced two negatively charged groups in positions 272-273 (Asp-Glu) resulted in refolding and exposure of transmembrane and cytoplasmic domains. Protein structure prediction was performed using the Phyre server (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) [173].
Figure 4
Figure 4
(A), Survival rate of strain 13 guinea pigs (4 animals per group) fatally infected with LASV (Jos, 1000 PFU, s.c.) and treated on day 2 and 4 after challenge with ML29 (1000 PFU, s.c.); (B), ML29 preventive efficacy in common marmosets. Animals (6 animals per group) were vaccinated with ML29 and challenged on day 30 with LASV (Jos) [143].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McCormick J.B., Fisher-Hoch S.P. Lassa fever. Curr. Top. Microbiol. Immuno.l. 2002;262:75–109. - PubMed
    1. Khan S.H., Goba A., Chu M. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antivir. Res. 2008;78:103–115. - PubMed
    1. Fichet-Calvet E., Rogers D.J. Risk Maps of Lassa Fever in West Africa. PLoS Negl. Trop. Dis. 2009;3 - PMC - PubMed
    1. Loureiro M.E., Wilda M., Levingston-Macleod J.M. Molecular determinants of Arenavirus Z protein homo-oligomerization and L polymerase binding. J. Virol. 2011 JVI.05691-05611. - PMC - PubMed
    1. Richmond J.K., Baglole D. Lassa fever: epidemiology, clinical features, and social consequences. BMJ. 2003;327:1271–1275. doi: 10.1136/bmj.327.7426.1271. - DOI - PMC - PubMed

Publication types

LinkOut - more resources